Therapeutic Indications

Aceclofenac is indicated for:

Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis

Irrespective of gender only Adults (18 years old or older)

Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 200 mg daily

Treatment 2: Cutaneous - 2 spreads a day

Contraindications

Active ingredient Aceclofenac is contraindicated in the following cases:

Severe renal failure

No gender/age discrimination

Aceclofenac should not be prescribed in severe renal failure.

Severe heart failure

No gender/age discrimination

Aceclofenac should not be prescribed in severe heart failure.

Severe hepatic failure

No gender/age discrimination

Aceclofenac should not be prescribed in severe hepatic failure.

Pregnancy

No gender/age discrimination

Aceclofenac should not be prescribed during pregnancy, especially during the last trimester of pregnancy, unless there are compelling reasons for doing so. The lowest effective dosage should be used.

Congenital abnormalities have been reported in association with NSAID administration in man; however, these are low in frequency and do not appear to follow any discernible pattern. In view of the known effects of NSAIDs on the foetal cardiovascular system (risk of closure of the ductus arteriosus) and on the possible risk of persistent pulmonary hypertension of the new born, use in the last trimester of pregnancy is contraindicated. The regular use of NSAIDs during the last trimester of pregnancy may decrease uterine tone and contraction. The onset of labour may be delayed and the duration increased with an increased bleeding tendency in both mother and child. NSAIDs should not be used during the first two trimesters of pregnancy or labour unless the potential benefit to the patient outweighs the potential risk to the foetus.

Animal studies indicate that there was no evidence of teratogenesis in rats although the systemic exposure was low and in rabbits, treatment with aceclofenac (10 mg/kg/day) resulted in a series of morphological changes in some foetuses.

In limited studies so far available, NSAIDs can appear in breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.

The use of aceclofenac should therefore be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the foetus.

Mifepristone

No gender/age discrimination

NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.

Bbleeding

No gender/age discrimination

Aceclofenac should not be prescribed in bleeding.

Peptic ulcer/haemorrhage

No gender/age discrimination

Aceclofenac should not be prescribed in active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).

Haemorrhagic disorders

No gender/age discrimination

Aceclofenac should not be prescribed in haemorrhagic disorders.